Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities

Area of Science:

• Pediatric neuro-oncology
• Cancer genomics
• Epigenetics

Background:

• Pineoblastoma (PB) is a rare, lethal pediatric brain cancer originating in the pineal gland.
• Current treatments offer limited survival rates, especially for metastatic disease, and cause significant neurocognitive deficits.
• PB comprises distinct molecular subtypes with varying prognoses, including those driven by DICER/DROSHA, RB1, and cMYC.

Purpose of the Study:

• To advance the understanding of pineoblastoma heterogeneity and progression.
• To highlight the importance of preclinical models for therapeutic development.
• To identify potential vulnerabilities for novel treatment strategies.

Main Methods:

• Review of recent advancements in pineoblastoma research, including molecular subtyping.
• Discussion of established and emerging preclinical models for PB subtypes.
• Analysis of disease mechanisms, cell of origin, and therapeutic targets.

Main Results:

• Pineoblastoma is classified into major subtypes based on genetic drivers (DICER/DROSHA loss, RB1 loss, cMYC amplification).
• Mouse models have been successfully developed for RB1-, DICER1-, and DROSHA-driven PB, but not yet for MYC-driven PB.
• Progress has been made in understanding PB biology, including tumor progression and the role of autophagy.

Conclusions:

• Subtyping and preclinical models are crucial for developing precision therapies for pineoblastoma.
• Further research into MYC-driven PB and targetable vulnerabilities is needed.
• Improved understanding holds promise for novel therapeutic strategies against this childhood malignancy.